03 January 2019
LexaGene was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018.
10 December 2018
LexaGene announces completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority of all clinical canine UTI cases.
03 December 2018
LexaGene recently had an Industry Engagement Meeting with the Department of Homeland Security (DHS) regarding the applications of the company’s technology for DHS’ program on Countering Weapons of Mass Destruction (CWMD).
28 November 2018
LexaGene named one of the 10 Most Promising Food and Beverages Solution Providers in 2018 by CIOReview.
22 October 2018
LexaGene successfully unveils LX2™ beta prototype design on October 20th, 2018 to an enthusiastic gathering of veterinary professionals at the American Association of Veterinary Laboratory Diagnosticians (AAVLD) conference.
09 October 2018
LexaGene to unveil LX2™ Beta Prototype design for the veterinary market at an upcoming industry event.
04 September 2018
LexaGene announces that company President, Daryl Rebeck, will present at two upcoming investor conferences that are taking place in September 2018
26 July 2018
LexaGene announces that the company has begun beta development of its flagship pathogen detection system.
11 July 2018
LexaGene completes C$5.75 Million Bought Deal Financing. Underwriters Exercise Over-Allotment Option in Full.
19 June 2018
LexaGene announces C$5.0 Million bought deal with a syndicate of underwriters led by Canaccord Genuity Corp.
18 June 2018
LexaGene names medical device veteran Joseph Caruso to Board of Directors. Mr. Caruso was responsible for the successful worldwide commercial launch of dozens of medical devices over his 30-year career.
06 June 2018
LexaGene announces a collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory to begin testing canine dog urine samples on LexaGene’s LX6 prototype.